Alzheimer/Dementia

Table of Contents

Studies

Studies #

The therapeutic potential of the endocannabinoid system for Alzheimer’s disease
Endocannabinoid signalling in Alzheimer’s disease
A molecular link between the active component of marijuana and Alzheimer’s disease pathology
Neuroprotective effect of CBD… on beta-amyloid-induced toxicity in PC12 cells
The Potential Therapeutic Effects of THC on Alzheimer’s Disease
The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer’s Disease
CBD in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression
CBD: A promising drug for neurodegenerative disorders?
Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition
The role of the endocannabinoid system in Alzheimer’s disease
The role of phytochemicals in the treatment and prevention of dementia
Cannabinoids for the treatment of dementia
Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression inSHSY5YAPP+ Cells Through PPARγ Involvement
Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia
Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease
Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model
CBD Modulates the Expression of Alzheimer’s Disease-Related Genes in Mesenchymal Stem Cells
In vivo Evidence for Therapeutic Properties of CBD for Alzheimer’s Disease
Neurological aspects of medical use of CBD
Amyloid-beta inhibits E-S Potentiation through suppression of cannabinoid receptor 1-dependent synaptic disinhibition
Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids
Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer’s disease
Alzheimer’s disease; taking the edge off with cannabinoids?
Cannabinoids and Dementia: A Review of Clinical and Preclinical Data
Cannabinoids and Parkinson’s disease
Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease
Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
Cannabinoids for the treatment of dementia
Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease
CB2 Cannabinoid Receptor As Potential Target against Alzheimer’s Disease
Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia
Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells
Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation
Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: An-open label, add-on, pilot study
Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer’s disease
Synthetic cannabinoids in dementia with agitation: Case studies and literature review
The influence of cannabinoids on generic traits of neurodegeneration
The potential therapeutic effects of THC on Alzheimer’s disease
The role of the endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer’s disease

What are your Feelings

Still stuck? How can we help?